STRIDE
66 evidence topics · 12 sources
Objective
Objective in the published article
Main and secondary objectives in the EU Clinical Trials Register
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2022-09-27” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2023-06-29” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2023-07-25” (opens the source at this quote in a new tab)
“First Posted 2022-10-31” (opens the source at this quote in a new tab)
“Results First Posted 2024-07-23” (opens the source at this quote in a new tab)
Number of sites in the published article, the ClinicalTrials.gov record, and the protocol
Countries of trial sites in the ClinicalTrials.gov record
| Country | First site listed for the country in the record |
|---|---|
| United States | “Birmingham, Alabama, United States, 35205” |
| Canada | “Edmonton, Alberta, Canada, T6G 1C3” |
| Czechia | “Nový Jičín, Czechia, 741 01” |
Planned regions, planned sites, authorization dates, and end date in the EU Clinical Trials Register
“E.8.5.1 Number of sites anticipated in the EEA 15” (opens the source at this quote in a new tab)
“Date of Competent Authority Decision 2023-01-30” (opens the source at this quote in a new tab)
“Date of Ethics Committee Opinion 2023-02-07” (opens the source at this quote in a new tab)
“Date of the global end of the trial 2023-07-25” (opens the source at this quote in a new tab)
Study design
Randomized, double-blinded, placebo-controlled 16-week design with stratified randomization in the published article
Design in the ClinicalTrials.gov record
| Design field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |
Design fields in the EU Clinical Trials Register
“E.7.2 Therapeutic exploratory (Phase II) Yes” (opens the source at this quote in a new tab)
“E.8.1.4 Double blind Yes” (opens the source at this quote in a new tab)
“E.8.1.5 Parallel group No” (opens the source at this quote in a new tab)
“E.8.2.4 Number of treatment arms in the trial 6” (opens the source at this quote in a new tab)
“E.8.7 Trial has a data monitoring committee Yes” (opens the source at this quote in a new tab)
Study duration and safety monitoring committee in the protocol
Eligibility criteria
Inclusion criteria in the protocol
Exclusion criteria on psoriasis type, associated conditions, psoriatic arthritis, and pregnancy in the protocol
Exclusion criteria on prior treatment washout and lack of response to biologic therapies in the protocol
Exclusion criteria on QTcF, cardiovascular disease, infections, and laboratory values in the protocol
“20. Has any of the following lab abnormalities:” (opens the source at this quote in a new tab)
“Absolute neutrophil count <1.5 X 10^9/L” (opens the source at this quote in a new tab)
“Hemoglobin <9 g/dL” (opens the source at this quote in a new tab)
“AST/ALT ≥2 x upper limit of normal (ULN)” (opens the source at this quote in a new tab)
“Albumin <3 g/dL” (opens the source at this quote in a new tab)
Exclusion criteria on corticosteroid-requiring conditions, malignancy, live vaccines, surgery, and mental illness in the protocol
Body mass index added to the weight criterion in the EU Clinical Trials Register
Eligibility criteria summarized in the supplementary material of the published article
Treatment
Dose groups, randomization, administration, and placebo matching in the published article
Arms and tablet regimens in the ClinicalTrials.gov results
| Arm | Arm description in the results |
|---|---|
| ESK-001 10 mg QD | “ESK-001 10mg tablet once a day” |
| ESK-001 20 mg QD | “ESK-001 20mg tablet once a day” |
| ESK-001 40 mg QD | “ESK-001 40mg tablet once a day” |
| ESK-001 20 mg BID | “ESK-001 20mg tablet twice a day” |
| ESK-001 40 mg BID | “ESK-001 40mg tablet twice a day” |
| Placebo | “Placebo tablet” |
Randomization ratio across five dose levels and placebo in the protocol
Study outcomes
Rationale for using PASI 75 response as the primary endpoint
Primary, secondary, and exploratory efficacy end points in the published article
Safety and pharmacokinetic outcomes in the published article
Primary and secondary outcome measures in the ClinicalTrials.gov record
Pharmacokinetic outcome measures at registration, October 2022, superseded in June 2024
Primary and secondary end points in the EU Clinical Trials Register
Exploratory end points in the protocol
PASI and sPGA scoring and the timepoint of the PASI-based end points in the protocol
Responder definitions for DLQI and pruritus NRS in the statistical analysis plan
Regulatory guidance on dose-finding designs and on the duration needed to show short-term efficacy
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation in the published article
Planned enrollment and sample size assumptions in the protocol
Estimated enrollment at registration in the ClinicalTrials.gov record
Actual enrollment in the ClinicalTrials.gov record
Participants per arm in the intent-to-treat, modified intent-to-treat, and safety analysis sets of the published article
| Analysis set (table) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Intent-to-treat (Table I) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 40)” | “(N = 39)” | “(N = 39)” |
| Modified intent-to-treat (Table II) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |
| Safety (Table III) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |
| Analysis set (table) | Pooled ESK-001 column header |
|---|---|
| Intent-to-treat (Table I) | “ESK-001 pooled (N = 190)” |
| Safety (Table III) | “ESK-001 pooled (N = 189)” |
Description of analysis sets
Efficacy and safety analysis populations, statistical tests, and missing-data handling in the published article
Analysis sets named in the table captions and notes of the published article
Analysis populations, stratification factors, multiplicity, and treatment-emergent period in the statistical analysis plan
Intent-to-treat efficacy analysis planned in the protocol
Analysis population for each outcome measure in the ClinicalTrials.gov results
| Outcome measure | Analysis population description |
|---|---|
| PASI-75 (primary) | “Analysis Population Description All Randomized and Treated Participants” |
| Safety and tolerability | “Analysis Population Description Safety Analysis Set” |
| sPGA response | “Analysis Population Description mITT population” |
| Pharmacokinetics | “Analysis Population Description PK Analysis Set” |
Results
Participant disposition
Randomized, dosed, completed, and discontinued participants in the published article
Participant flow by arm with reasons for not completing in the ClinicalTrials.gov results
| Participant flow, overall study | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Started | “38” | “36” | “36” | “40” | “39” | “39” |
| Completed | “33” | “36” | “30” | “37” | “33” | “35” |
| Not completed | “5” | “0” | “6” | “3” | “6” | “4” |
| Reason: adverse event | “0” | “0” | “2” | “0” | “1” | “1” |
| Reason: discontinued prior to dosing due to the blood sample logistics | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: lost to follow-up | “0” | “0” | “2” | “1” | “1” | “0” |
| Reason: protocol violation | “0” | “0” | “0” | “0” | “2” | “0” |
| Reason: subject can't continue with week 16 visit | “0” | “0” | “1” | “0” | “0” | “0” |
| Reason: terminated from the study due to sponsor requirements | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: withdrawal by subject | “5” | “0” | “1” | “0” | “2” | “3” |
Baseline characteristics
Demographic and baseline disease characteristics by arm in the intent-to-treat set
Balance across arms and overall prior biologic or JAK inhibitor exposure in the published article
Age categories by arm in the ClinicalTrials.gov results
| Age category, participants | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 40 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 | Total, n = 228 |
|---|---|---|---|---|---|---|---|
| 18 years or younger | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Between 18 and 65 years | “35” | “33” | “33” | “35” | “37” | “33” | “206” |
| 65 years or older | “3” | “3” | “3” | “5” | “2” | “6” | “22” |
Efficacy results
PASI 75, PASI 90, PASI 100, sPGA 0/1, sPGA 0, and BSA results at week 12 by dose in the modified intent-to-treat set
Primary end point, dose-dependent response, and key secondary end points in the published article
Maintenance of PASI 75 and PASI 90 responses during the 4 weeks off treatment, and response trajectories at week 12
PASI 75 response rates with 95% confidence intervals in the ClinicalTrials.gov results
| Week 12 outcome | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 39 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 |
|---|---|---|---|---|---|---|
| PASI-75, percentage (95% CI) | “0 (0.0 to 9.3)” | “19.4 (8.2 to 36.0)” | “33.3 (18.6 to 51.0)” | “56.4 (36.6 to 72.2)” | “56.4 (39.6 to 72.2)” | “64.1 (47.2 to 78.8)” |
Plasma ESK-001 concentrations by dose in the ClinicalTrials.gov results
| Plasma ESK-001 concentration, ng/ml | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Mean (SD) | “2.9(10.5)” | “11.9(12.4)” | “33.0(49.9)” | “63.9(44.8)” | “50.7(44.8)” | “174.0(125.0)” |
Dose-proportional pharmacokinetics, exposure-response, and trough coverage of the IC90 in the published article
Blood SIGLEC1 and lesional skin biomarker results in the published article
Exploratory exposure-response analysis and selection of the 40 mg twice-daily dose for phase 3
Health-related quality of life and patient-reported outcomes
DLQI 0/1, DLQI 4-point decrease, and pruritus NRS results at week 12 by dose in the modified intent-to-treat set
| Week 12 patient-reported outcome | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
|---|---|---|---|---|---|---|
| DLQI-0/1, n (%) | “7 (18)” | “10 (28)” | “12 (33)” | “20 (51)” | “19 (48)” | “25 (64)” |
| DLQI-0/1, P value vs placebo | “-” | “.2807” | “.1159” | “.0016” | “.0045” | “<.0001” |
| DLQI-0/1, difference vs placebo, % (95% CI) | “-” | “9 (−10, 29)” | “15 (−5, 35)” | “33 (13, 53)” | “30 (10, 50)” | “46 (26, 65)” |
| DLQI 4-point decrease, n (%) | “7 (19)” | “18 (51)” | “18 (51)” | “25 (64)” | “26 (70)” | “24 (65)” |
| DLQI 4-point decrease, P value vs placebo | “-” | “.0032” | “.0032” | “.0001” | “<.0001” | “<.0001” |
| DLQI 4-point decrease, difference vs placebo, % (95% CI) | “-” | “33 (12, 53)” | “33 (12, 53)” | “45 (26, 65)” | “51 (32, 71)” | “46 (26, 66)” |
| Mean change from baseline in average pruritus NRS (SD) | “−1 (3)” | “−2 (3)” | “−3 (3)” | “−4 (3)” | “−4 (3)” | “−5 (3)” |
| Mean change from baseline in worst pruritus NRS (SD) | “−1 (3)” | “−3 (3)” | “−3 (4)” | “−4 (3)” | “−5 (3)” | “−5 (3)” |
| Average pruritus NRS score <4, n (%) | “11 (29)” | “17 (47)” | “21 (58)” | “27 (69)” | “27 (69)” | “28 (72)” |
| Worst pruritus NRS score <4, n (%) | “10 (26)” | “17 (47)” | “18 (50)” | “26 (67)” | “27 (69)” | “29 (74)” |
DLQI 0/1 and average pruritus NRS improvement with 40 mg twice daily in the published article
Median change in average and worst pruritus NRS at week 12 by dose in the congress poster
| Week 12 pruritus NRS change from baseline, median (IQR) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
|---|---|---|---|---|---|---|
| Average pruritus NRS | “0.0 (-3.0, 1.0)” | “-2.0 (-3.0, 0.0)” | “-2.5 (-6.0, 0.0)” | “-3.0 (-5.0, -2.0)” | “-5.0 (-6.0, -3.0)” | “-4.0 (-8.0, -3.0)” |
| Worst pruritus NRS | “-0.5 (-2.0, 1.0)” | “-2.0 (-4.0, -1.0)” | “-2.5 (-5.0, 1.0)” | “-4.0 (-6.0, -1.0)” | “-5.0 (-7.0, -3.0)” | “-5.0 (-7.0, -3.0)” |
DLQI reductions of at least 4, 5, and 6 points with 40 mg twice daily and pruritus NRS of 3 or less in the congress poster
EQ-5D results
No evidence found.
Safety results
Treatment-emergent adverse events by dose in the safety analysis set
| Outcome, n (%) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 | ESK-001 pooled, N = 189 |
|---|---|---|---|---|---|---|---|
| TEAEs | “15 (39.5)” | “19 (52.8)” | “14 (38.9)” | “18 (46.2)” | “19 (48.7)” | “25 (64.1)” | “95 (50.3)” |
| TEAEs leading to treatment discontinuation | “0 (0.0)” | “0 (0.0)” | “2 (5.6)” | “0 (0.0)” | “2 (5.1)” | “1 (2.6)” | “5 (2.6)” |
| TEAEs grade 3 or higher | “0 (0.0)” | “3 (8.3)” | “1 (2.8)” | “3 (7.7)” | “3 (7.7)” | “0 (0.0)” | “10 (5.3)” |
| TEAEs related to study drug | “5 (13.2)” | “3 (8.3)” | “3 (8.3)” | “5 (12.8)” | “7 (17.9)” | “9 (23.1)” | “27 (14.3)” |
| Headache | “2 (5.3)” | “0 (0.0)” | “2 (5.6)” | “3 (7.7)” | “4 (10.3)” | “3 (7.7)” | “12 (6.3)” |
| Upper respiratory tract infection | “0 (0.0)” | “2 (5.6)” | “2 (5.6)” | “1 (2.6)” | “2 (5.1)” | “3 (7.7)” | “10 (5.3)” |
| Nasopharyngitis | “3 (7.9)” | “2 (5.6)” | “0 (0.0)” | “1 (2.6)” | “1 (2.6)” | “3 (7.7)” | “7 (3.7)” |
| SAEs | “0 (0.0)” | “1 (2.8)” | “0 (0.0)” | “3 (7.7)” | “1 (2.6)” | “0 (0.0)” | “5 (2.6)” |
| Deaths | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
Overall tolerability, common adverse events, and absence of tuberculosis, herpes zoster, opportunistic infections, and oral ulcers in the published article
Serious adverse events by arm, with the gastrointestinal event in the 20 mg twice-daily arm reported as enterocolitis, enteritis, or colitis and enteritis
| Serious adverse event, affected / at risk (%) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Total | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “3/39 (7.69%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Coronary artery occlusion | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Colitis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Enteritis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Lower limb fracture | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Tibia fracture | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Dermatitis contact | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
Other adverse events reported in at least 5% of participants in any arm in the ClinicalTrials.gov results
Absence of dose-dependent safety signals and of JAK inhibitor-associated adverse events in the discussion of the published article
Absence of MACE, serious infections, treatment-related thromboses, and laboratory or ECG trends in the congress presentation
Study limitations
Summary
- The authors cite the small sample size per treatment group and the 16-week study duration, and the exclusion of participants who were previously nonresponders to IL-17, IL-12, or IL-23 targeted therapies. The protocol also excluded participants with lack of response to 2 or more biologic therapies.
- The primary endpoint was assessed at week 12, when, according to the authors, response trajectories suggested maximal efficacy had not yet been achieved.
- The statistical analysis plan states that no adjustments for multiplicity were performed.
- The analysis population for efficacy differs by source: the protocol planned intent-to-treat analyses, the article used the modified intent-to-treat population, and the ClinicalTrials.gov results describe the PASI 75 population as all randomized and treated participants. The 20 mg BID arm has 40 participants in the intent-to-treat set and 39 in the modified intent-to-treat and safety sets.
- The number of sites is 30 in the article, 53 in the ClinicalTrials.gov record, and approximately 65 planned in the protocol.
- The serious gastrointestinal event in the 20 mg BID arm is reported as enterocolitis (article table footnote), enteritis of unknown etiology (article text), colitis and enteritis as separate terms (ClinicalTrials.gov results), and colitis and enteritis in one subject (congress presentation).
- The article reports 5 participants (2.6%) discontinuing envudeucitinib due to an AE; the ClinicalTrials.gov participant flow lists an adverse event as the reason for not completing the study for 2 (20 mg QD), 1 (40 mg QD), and 1 (40 mg BID) participants.
- The DLQI decrease of at least 4 points with 40 mg BID is 65% in the article and 62% in the patient-reported outcomes poster.
- Acne and folliculitis rates are cited as data on file, skin biopsies were optional and collected from approximately 5 to 12 participants per dose group, and the report holds no EQ-5D results.